Drugs / CM350
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05263960 | Apr 2022 → Apr 2027 expected | neoplasm | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM350 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05263960 ↗ |
| Route | Intravenous | “CM350 will be administered intravenously (IV)” NCT05263960 ↗ |